Board of Directors

David G.P. Allan, Chairman of the Board

Thomas I.A. Allen, Q.C., F.C.I.Arb, Director, Governance & Nominating Committee Chair

Mark Entwistle, M.A., Director, Compensation Committee Chair

Henry Friesen, C.C., M.D., F.R.S.C., Director

Philip Frost, M.D., Ph.D., Director

François Thomas, M.D., Director

Robert C.G. Watson, Director

Gilbert Wenzel, Ph.D., Director

Tryon M. Williams, B.Sc., Director, Audit Committee Chair


David G.P. Allan
Chairman, Chief Executive Officer and Director
Mr. Allan has been Chief Executive Officer of the Company since April 1998 and Chairman of the board of directors of the Company since 1994. In addition, Mr. Allan is a Director of Synthemed Inc. (medical devices) USA and DiaMedica Inc. (diabetes therapeutics) Canada. In 1992 he founded the Knowledge-Based Industries Group of a Canadian investment banking firm, organized as the first in Canada involved in financing, analyzing and creating strategic alliances for life sciences and information technology companies, where he was Executive Director until 1998. Mr. Allan was formerly a governor of The Toronto Stock Exchange, a member of the Awards Selection Committee for the Networks of Centres of Excellence in Canada, working group Chair of the Ontario Biotechnology Advisory Board and a member of the Board of Trustees for the Ontario College of Art and Design. Mr. Allan is currently a member of BIOTECanada's Emerging Companies Advisory Board.

return to top

Thomas I.A. Allen, Q.C., F.C.I.Arb
Director, Governance & Nominating Committee Chair

Mr. Allen is counsel to Ogilvy Renault, a Canadian law firm. Mr. Allen was the initial Chairman of the Accounting Standards Oversight Council of Canada and was a member of the Advisory Board of the Office of the Superintendent of Financial Institutions of Canada. He is currently a director of a number of public companies including Terra Nova Gold Inc., Mundoro Mining Inc., Middlefield Bancorp Limited, and Thomas Weisel Group Inc. Mr. Allen recently acted as Chairman of the Task Force to Modernize Securities Legislation in Canada. Mr Allen has been a director of the Company since 1996.

 

return to top

 

Mark Entwistle, M.A.
Director, Compensation Committee Chair

Prior to founding his own consulting practice in 1997 in international trade, political business intelligence and strategic communications, Mr. Entwistle was Ambassador for Canada to Cuba from 1993 to 1997. Mr. Entwistle was previously a career diplomat with the Canadian Department of Foreign Affairs and International Trade in a variety of embassy positions from 1982 to 1997, and served as Press Secretary and Director of Communications to the Prime Minister of Canada from 1991-1993. He is a Fellow of the Canadian Defence and Foreign Affairs Institute. Mr. Entwistle has been a director of the Company since October 1997.

return to top

Henry Friesen, C.C., M.D., F.R.S.C.
Director

Dr. Friesen currently serves as Chair of the Gairdner Foundation whose international awards are Canada's most prestigious prizes in the biomedical sciences. He was most recently Chair, Genome Canada, 2000-2005; a $600 million budget non-profit organization that supports genomics/proteomics programs to position Canada as a world leader in selected areas in this important sector. From 1991 to 2000 Dr. Friesen was President of the Medical Research Council of Canada and was instrumental in transforming it into the Canadian Institutes of Health Research, an organization with an annual budget in 2008 of over $900 million dedicated to supporting Canadian researchers as well as industry participants. Dr. Friesen is noted for his discoveries of the human hormone prolactin. For 19 years he was Head of the Department of Physiology at the University of Manitoba and now is Distinguished University Professor Emeritus. Dr. Friesen is a Fellow of the Royal Society of Canada, a Companion of the Order of Canada recipient of 8 honorary degrees and also sits on the board of directors of Sanofi Pasteur Canada and Spectral Diagnostics Inc. Dr. Friesen has been a director of the Company since November 2001.

return to top

Philip Frost, M.D., Ph.D.
Director

Dr. Frost is currently the President of Calesca Pharmaceuticals. In 2005, Dr. Frost was appointed Executive Vice-President and Chief Scientific Officer at ImClone where he oversaw the company's research, clinical and regulatory departments. He subsequently held the post of Interim Chief Executive Officer until December 2006. Prior to ImClone, Dr. Frost served as Vice President of Oncology and Co-Director of the Oncology Therapeutic Area Leadership Team at Wyeth, where he was responsible for the development of various oncology compounds and contributed to the approval and commercialization of Mylotarg® for the treatment of a specific form of acute myeloid leukemia. Dr. Frost has held the positions of Adjunct Professor of Cell Biology and Adjunct Professor of Medicine at The University of Texas M.D. Anderson Cancer Center. He is also a Director of Innovive Pharmaceuticals, a New York-based oncology company and a Director of Avalon Pharmaceuticals. Dr. Frost has been a director of the Company since 2007.

return to top

François Thomas, M.D.
Director

Dr. Thomas, a board certified medical oncologist, is a member of the Board of Directors of Unibioscreen, Eurogentec and DNA therapeutics, and formerly was a Director of Newron, Entomed, Neurotech, Novexel and CropDesign. Dr. Thomas is currently a Senior Advisor at Bryan Garnier, a Paris-based investment back, and is responsible for corporate finance activities for pharmaceutical and biotechnology companies. Dr. Thomas has been a Venture Partner at Atlas Venture (London, UK), and a General Manager at Bioserve Ltd. (Cambridge, UK), a consultancy for the life sciences arena. He was previously Vice President Licensing, Medical Affairs and Pharmacogenomics at Genset (Paris, France), Vice President, Clinical Development at Ipsen (Paris, France) and Assistant Professor of Medical Oncology at Institut Gustave Roussy (Paris, France). Dr. Thomas has been a director of the Company since 2007.

return to top

Robert C.G. Watson
Director
Mr. Watson is currently Chair of SEEK.com, one of Australia's most successful internet businesses with operations in Australia, New Zealand, China and Brazil. He was Chair of Cytopia Ltd., a biotech company acquired by YM BioSciences in January 2010. He was also a non-executive director of Virgin Blue, an Australian national and international airline. Mr. Watson has over 25 years experience at the CEO and board level in the Information Technology industry in Australia, UK and USA. He was CEO of Computer Technology,  Data Sciences International, Mayne Nickless Computer Services and ICON. In addition, he has founded and developed several private IT software, services and consulting businesses. Mr. Watson was also a non-executive director and advisor to Nextec, a leading Australian Investment Bank specializing in the Technology sector. Mr. Watson has been a director of the company since January 2010.

return to top

Gilbert Wenzel, Ph.D.
Director
Dr. Wenzel is currently Chairman of QUISISANA HOLDING AG and Chief Executive Officer, a pharma company focused on importing, registering and commercializing generics for private label use by pharmacy chains and insurance companies in Europe. Prior to founding Quisisana in January 2003, Dr. Wenzel joined Novartis Group, a global pharmaceutical manufacturer, in November 2000 where he served as Head of Strategic Planning and a Member of its Executive Committee until January 2003. Prior to joining Novartis, Dr. Wenzel spent 15 years with McKinsey & Co., an international management consulting firm, and was a member of the European Leadership Group of its Pharma/Healthcare Sector and of the European New Venture Initiative. From 1981 to 1985, Dr. Wenzel was at Hoechst AG in Germany and developed global strategies for generics and over-the-counter medicines. Dr. Wenzel has been a director of the Company since March 2001.

return to top

Tryon M. Williams, B.Sc. (Math)
Director, Audit Committee Chair

Mr. Williams is the Chairman, CEO and director of Bingo.com, Ltd., an internet technology company and Chairman and director of CellStop International Ltd., an automobile security device manufacturer. From 1993 to 2007, Mr. Williams was Adjunct Professor, Sauder School of Business, The University of British Columbia. Mr. Williams is also a director of several other private corporations. Mr. Williams has been a director of the Company since November 1995.

return to top